SCHEMBL30793390

SCHEMBL30793390

CNC(=O)c1nn2c(c1OC)CN(C(=O)OC(C)(C)C)CCC2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 2/20 0.36
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MAPT P10636 2/20 0.34
▸ MMP1 P03956 1/20 0.34
▸ MMP9 P14780 1/20 0.34
▸ MMP13 P45452 1/20 0.34
▸ HPGD P15428 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ CYBB P04839 1/20 0.33
▸ NOX5 Q96PH1 1/20 0.33
▸ NOX4 Q9NPH5 1/20 0.33
▸ NOX1 Q9Y5S8 1/20 0.33
▸ PDE4A P27815 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ JAK1 P23458 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30793750 0.87 ADORA1 (0.39) NR1H2MEN1KMT2AMAPTMMP1
SCHEMBL25337124 0.86 KMT2A (0.36) NR1H2MEN1KMT2AMAPTHPGD
SCHEMBL30793338 0.85 MAPT (0.37) NR1H2MEN1KMT2AMAPTHPGD
SCHEMBL30793157 0.83 ADORA1 (0.44) NR1H2MEN1KMT2AMAPTHPGD
SCHEMBL25338426 0.78 NR1H2 (0.43) NR1H2MEN1KMT2AMAPTMMP1
SCHEMBL30793378 0.78 NR1H2 (0.43) NR1H2MEN1KMT2AMAPTMMP1
SCHEMBL25337280 0.77 NR1H2 (0.42) NR1H2MEN1KMT2AMAPTMMP1
SCHEMBL25335700 0.77 NR1H2 (0.42) NR1H2MEN1KMT2AMAPTMMP1
SCHEMBL30793876 0.77 NR1H2 (0.42) NR1H2MEN1KMT2AMAPTMMP1
SCHEMBL30793644 0.77 MEN1 (0.34) NR1H2MEN1KMT2AMAPTMMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2025-12-04 — — US disclosed
EP-4540254-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2023244604-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS NR1H2 2340/4885MEN1 948/4885KMT2A 1207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback